William
S. Dalton, Ph.D., M.D.
Director of Moffitt Cancer Center
Professor of Oncology
E-mail:
William.Dalton@moffitt.org
Phone:
813-745-1421
Training
Ph.D., Indiana University, Toxicology and Medical Life Sciences
M.D.,
Indiana University
Internship, Indiana University
Residency, University of Arizona
Fellowships in Oncology and Clinical Pharmacology at the University of
Arizona
Research
Interests
Dr. Dalton's laboratory research is focused in the area of drug resistance
in cancer cells. There are three main areas of ongoing research in this
area. The first area concentrates on the mechanism of multidrug resistance
due to transport genes. These genes include the MDR1 gene, the MRP gene,
and the LRP gene. All three genes have been associated with enhanced drug
efflux and/or altered intracellular distribution of cytotoxic drugs. The
second area of research focuses on the role of the Fas/Fas ligand in drug
response. We have reported that cells selected for cytotoxic drug resistance
are also cross-resistant to Fas mediated apoptosis (Landowski, T. et al,
Blood 89: 1854-1861, 1997). Current research is focusing on the common
mediators associated with both drug and Fas response as well as resistance.
The third area of research involves studying cell adhesion molecules and
their role in drug resistance. Specifically, we have found that the beta-integrin,
VLA-4 is activated during selection for drug resistance and this activation
appears to mediate low levels of resistance. Research in this area is
focused on determining the mechanism by which VLA-4 activation causes
drug resistance in cancer.
Search
for publications by: 
This
search will be conducted at the US National Library of Medicine (NLM) and PubMed.
Selected
Publications
Hazlehurst LA, Foley NF, Guzman-Gleason MC, Cress AE, Hacker MP, Greenberger
LW, de Jong MC, Dalton WS. Multiple mechanisms confer drug resistance
to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 59:1021-1028,
1999.
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Nunez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human myeloma tumor cells. Immunity 10:105-115, 1999.
Shain K, Landowski T, Buyuksal I, Cantor A, Dalton WS. Clonal variability in CD95-expression is the major determinant in Fas-mediated, but not chemotherapy-mediated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia 14:830-840, 2000.
Scheffer GL, Maliepaard M, Pijnenborg A, van Gastelen M, de Jong M, Schroeijers A, van der Kolk D, Allen J, Ross D, van der Valk P, Dalton WS, Schellens J, Scheper RJ. BCRP is localized at the plasma membrane in mitoxantrone and topotecan resistant cell lines. Cancer Research (in press), 2000.
Hazlehurst L, Damiano J, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via b1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene (in press), 2000.
Cancer Biology Ph.D. Program
H. Lee Moffitt Cancer Center, MRC-4 East
12902 Magnolia Drive
Tampa, Florida 33612
Phone: 813-745-6876
E-mail: CancerPHD@moffitt.org
Copyright © 2000 University of South Florida